Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biosynexus Incorporated
Gaithersburg, Maryland, United Statesbiosynexus.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Biosynexus developed pagibaximab, a monoclonal antibody for preventing staphylococcal sepsis in neonates, which completed Phase I/II trials showing safety and opsonic activity. Lysostaphin was tested as an intranasal cream for eradicating nasal colonization by S. aureus and entered early clinical studies. The company also worked on nisin as a topical antibacterial agent. Some programs have been discontinued or are pending further development due to strategic shifts or acquisition[1][2][3].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodiesEnzymesPeptides
- Industry
- Biotech
02
Partnerships
GSK Biologicals ($120M deal)AMBI/Nutrition21 licensing deals
Beyond the preview
Go deeper on Biosynexus Incorporated.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biosynexus Incorporated.